[Comparison of dinitrate isosorbide retard forms in ischemic heart disease patients with stable effort angina]. / Sravnenie retardnykh form izosorbida dinitrata u bol'nykh IBS so stabil'noi stenokardiei napriazheniia.

AIM: To compare antianginal and anti-ischemic efficiency and tolerance of two forms of isosorbide dinitrate--cardiket-retard 120 mg and cardiket-retard 40 mg in IHD patients with stable effort angina. MATERIAL AND METHODS: The study included 18 IHD patients with stable angina of functional class II (5 patients) and III (13 patients). The trial was open cross-over. The treatment with both the forms lasted 1 month. Frequency of anginal attacks and exercise tolerance by veloergometry data were assessed. RESULTS: A significant decrease in the number of anginal attacks and greater exercise tolerance was recorded in cardiket 120 mg intake once a day. Both forms were well tolerated, serious side effects were absent. CONCLUSION: Comparison of the two isosorbide dinitrate dosage forms--cardiket 120 mg once a day and cardiket 40 mg 3 times a day--showed that the former is superior by clinical efficiency.

[Comparative study of retard and non-retard forms of isosorbide-5-mononitrate in coronary patients with stable angina pectoris]. / Sravnitel'noe izuchenie retardnoi i neretardnoi form izosorbid-5-mononitrata u bol'nykh ishemicheskoi bolezn'iu serdtsa so stabil'noi stenokardiei.

An open cross-over trial compared retard and non-retard forms of isosorbide-5-mononitrate (monomac 50D and isomonat, respectively) in 15 patients with stable angina of effort (functional class II-III). Both drugs were found rather effective, they significantly increase exercise tolerance. A single daily dose of monomac 50D reduced the number of anginal attacks. It was well tolerated, caused no serious side effects and had advantages over isomonat taken 2 or 3 times a day.